Pathologic Considerations and Standardization in Mesothelioma Clinical Trials

被引：10

作者：

Tsao, Ming-Sound ^{[1
,2
]}

Carbone, Michele ^{[3
]}

Galateau-Salle, Francoise ^{[4
]}

Moreira, Andre L. ^{[5
]}

Nicholson, Andrew G. ^{[6
,7
]}

Roden, Anja C. ^{[8
]}

Adjei, Alex A. ^{[9
]}

Aubry, Marie-Christine ^{[8
]}

Fennell, Dean A. ^{[10
]}

Gomez, Daniel ^{[11
]}

Harpole, David ^{[12
]}

Hesdorffer, Mary ^{[13
]}

Hirsch, Fred R. ^{[14
]}

Liu, Geoffrey ^{[15
]}

Malik, Shakun ^{[16
]}

Nowak, Anna ^{[17
]}

Peikert, Tobias ^{[18
]}

Salgia, Ravi ^{[19
]}

Szlosarek, Peter ^{[20
]}

Taioli, Emanuela ^{[21
,22
]}

Yang, Haining ^{[3
]}

Tsao, Anne ^{[23
]}

Mansfield, Aaron S. ^{[9
]}

机构：

[1] Princess Margaret Canc Ctr, Dept Pathol, Toronto, ON, Canada

[2] Univ Toronto, Toronto, ON, Canada

[3] Univ Hawaii, Canc Ctr, Thorac Oncol Program, Honolulu, HI 96822 USA

[4] Ctr Leon Berard, Dept BioPathol, MESOBANK, MESOPATH,MESONAT, Lyon, France

[5] New York Univ Langone Hlth, Dept Pathol, New York, NY USA

[6] Imperial Coll, Royal Brompton & Harefield NHS Fdn Trust, Dept Histopathol, London, England

[7] Imperial Coll, Natl Heart & Lung Inst, London, England

[8] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA

[9] Mayo Clin, Div Med Oncol, 200 First St SW, Rochester, MN 55905 USA

[10] Leicester Canc Res Ctr, Mesothelioma Res Programme, Leicester, Leics, England

[11] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA

[12] Duke Univ, Dept Surg, Div Cardiothorac Surg, Durham, NC USA

[13] Mesothelioma Appl Res Fdn, Alexandria, VA USA

[14] Tisch Canc Ctr, Ctr Thorac Oncol, Mt Sinai Hlth Syst, New York, NY USA

[15] Princess Margaret Canc Ctr, Toronto, ON, Canada

[16] NCI, Clin Invest Branch, Canc Therapy Evaluat Program, NIH, Bethesda, MD 20892 USA

[17] Univ Western Australia, Natl Ctr Asbestos Related Dis, Nedlands, WA, Australia

[18] Mayo Clin, Div Pulm & Crit Care Med, Rochester, MN USA

[19] City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA

[20] Queen Mary Univ London, Barts Canc Inst, London, England

[21] Icahn Sch Med Mt Sinai, Dept Epidemiol, New York, NY 10029 USA

[22] Icahn Sch Med Mt Sinai, Dept Thorac Surg, New York, NY 10029 USA

[23] Univ Texas MD Anderson Canc Ctr, Dept Thoracic Head & Neck Med Oncol, Houston, TX 77030 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期

关键词：

Mesothelioma; Clinical trials; Pathology; Correlatives; Pathologic classification; MALIGNANT PLEURAL MESOTHELIOMA; HEALTH-ORGANIZATION CLASSIFICATION; LIGAND; EXPRESSION; REPORTING RECOMMENDATIONS; BRCA1-ASSOCIATED PROTEIN-1; QUALITY-ASSURANCE; NEEDLE-BIOPSY; OPEN-LABEL; T-CELLS; LUNG;

D O I：

10.1016/j.jtho.2019.06.020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The accurate diagnosis of mesothelioma is critical for the appropriate clinical management of this cancer. Many issues complicate making the diagnosis of mesothelioma including the presence of reactive mesothelial cells in benign pleural effusions, the heterogeneity of mesothelioma histopathology, the relatively high incidence of other epithelial malignancies that metastasize to the pleura, and primary sarcomas that arise within the pleura. Given the rapidly evolving field of molecular profiling and the need for translational correlates in mesothelioma clinical trials, the National Cancer Institute (NCI)-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting was convened in March 2017 to develop a consensus on standard pathology guidelines for future NCI-sponsored clinical trials in mesothelioma. This consensus statement covers recommendations for specimen handling, pathologic classification and diagnosis, biobanking, and tissue correlative studies. (C) 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

引用

页码：1704 / 1717

页数：14

共 50 条

[21] Ethical considerations of clinical trials in the developing world
Fitchett, Joseph R.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2009, 103 (08) : 756 - 760
[22] Considerations in the Design of Clinical Trials for Cognitive Aging
Reiman, Eric M.
Brinton, Roberta Diaz
Katz, Russell
Petersen, Ronald C.
Negash, Selam
Mungas, Dan
Aisen, Paul S.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2012, 67 (07): : 766 - 772
[23] Clinical trials: Considerations for researchers and hospital administrators
Uecke, Oliver
Reszka, Regina
Linke, Joachim
Steul, Martina
Possel, Thorsten
HEALTH CARE MANAGEMENT REVIEW, 2008, 33 (02) : 103 - 112
[24] CLINICAL TRIALS IN DEVELOPING COUNTRIES - ETHICAL CONSIDERATIONS
Pasic, Marija Bosnjak
Vidrih, Branka
Sarac, Helena
Pasic, Hanna
Vujevic, Luka
Koruga, Anamarija Soldo
Rajic, Fabijan
PSYCHIATRIA DANUBINA, 2018, 30 (03) : 285 - 291
[25] Novel Therapies in Phase II and III Trials for Malignant Pleural Mesothelioma
Zauderer, Marjorie G.
Krug, Lee M.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012, 10 (01): : 42 - 47
[26] Oncology Nursing Considerations in a Clinical Trials Environment
Legor, Kristen
SEMINARS IN ONCOLOGY NURSING, 2020, 36 (03)
[27] From Standardization to Adaptation: Clinical Trials and the Moral Economy of Anticipation
Montgomery, Catherine M.
SCIENCE AS CULTURE, 2017, 26 (02) : 232 - 254
[28] New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical Trials
Travis, William D.
Brambilla, Elisabeth
Riely, Gregory J.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (08) : 992 - 1001
[29] Updates on the pathologic diagnosis and classification of mesothelioma
Farkas, Julia R.
Sharobim, Mark
Schulte, Jefree J.
JOURNAL OF CANCER METASTASIS AND TREATMENT, 2022, 8
[30] Pathologic Evaluation of Malignant Pleural Mesothelioma
Chirieac, Lucian R.
Corson, Joseph M.
SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2009, 21 (02) : 121 - 124

← 1 2 3 4 5 →